ABSORB II, challenging three-year data underlines concerns

Introducing a new device is a challenge from a conceptual, technical and clinical standpoint. Over the last few years, various presentations at EuroPCR and other international meetings – as well as significant coverage in EuroIntervention – have focused on the new bioresorbable vascular scaffolds. Three-year results from the ABSORB II trial, recently presented in America, cast a critical light on this technology and put into question the state of its current development. What these results could mean for the patient and cardiologist is of crucial importance. Putting this current data into the context of previous developments in the history of interventional cardiology can be an essential step in more fully understanding where we stand today. Future clinical achievements are built on experience, continuing research and hands-on work.

What follows is one step in that process…

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trialProf.Patrick W Serruys, MD, Bernard Chevalier, MD, Yohei Sotomi, MD, Angel Cequier, MD, Prof Jan J Piek, MD, Ad J Van Boven, MD, Prof Marcello Dominici, MD, Dariusz Dudek, MD, Dougal McClean, MD, Steffen Helqvist, MD, Prof. Michael Haude, MD, Sebastian Reith, MD, Manuel de Souza Almeida, MD, Gianluca Campo, MD, Andrès Iñiguez, MD, Manel Sabaté, MD, Prof. Stephan Windecker, MD, Yoshinobu Onuma, MD - The Lancet, 30 October 2016 -